AARTI DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 488.4 INR | -0.32% |
|
+3.49% | -0.12% |
| May. 06 | Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024 | |
| May. 03 | Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 25.29B 304M | Sales 2025 * | 27.64B 332M | Capitalization | 45.05B 541M |
|---|---|---|---|---|---|
| Net income 2024 | 1.71B 20.59M | Net income 2025 * | 2.38B 28.52M | EV / Sales 2024 | 1.58 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.63 x |
| P/E ratio 2024 |
23.4
x | P/E ratio 2025 * |
19.1
x | Employees | 1,003 |
| Yield 2024 * |
0.96% | Yield 2025 * |
1.31% | Free-Float | 36.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aarti Drugs Limited
| 1 day | -0.32% | ||
| 1 week | +3.49% | ||
| Current month | -3.19% | ||
| 1 month | -1.57% | ||
| 3 months | -9.86% | ||
| 6 months | +2.79% | ||
| Current year | -0.12% |
1 week
453.65
492.65
1 month
453.60513.20
Current year
430.00567.10
1 year
430.00645.00
3 years
310.80778.15
5 years
104.831 025.00
10 years
46.381 025.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 85-01-04 | |
Adhish P. Patil
DFI | Director of Finance/CFO | 41 | 12-07-05 |
Rushikesh Deole
CMP | Compliance Officer | - | 19-04-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 85-01-04 | |
| Director/Board Member | 61 | 87-01-01 | |
| Director/Board Member | 60 | 95-09-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +5.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 490 | +0.85% | 13,315 |
| 24-05-16 | 485.8 | +1.18% | 4,423 |
| 24-05-15 | 480.2 | +1.29% | 6,651 |
| 24-05-14 | 474.1 | +0.44% | 6,628 |
| 24-05-13 | 472 | +2.14% | 11,279 |
Delayed Quote Bombay S.E., May 18, 2024 at 03:00 am EDT
More quotes
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
490
INR
Average target price
542
INR
Spread / Average Target
+10.61%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.12% | 541M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- AARTIDRUGS Stock
